Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT

A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels \<360 μmol/L at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.

NCT Number	NCT07326839
Lead Sponsor	XueMei Guo Collaborators: Shengjing Hospital, The People's Hospital of Liaoning Province
Conditions	Gout, Obesity
Enrollment	120 participants
Start Date	2025-12-10
Primary Completion	2027-11-09 (estimated)
Study Completion	2027-11-09 (estimated)
Updated on ClinicalTrials.gov	2026-01-08